Summary |
|
||||||||||||
Transgene origin |
|
||||||||||||
Transgene description |
|
||||||||||||
Phenotypes |
View phenotypes and curated references for all genotypes (concatenated display).
|
||||||||||||
Disease models |
|
||||||||||||
Expression |
|
||||||||||||
Tumor Data |
|
||||||||||||
Find Mice (IMSR) |
|
||||||||||||
Notes |
Homozygous transgenic mice are viable, fertile, normal in size, and do not display any gross physical or behavioral abnormalities.
Transgenic mice express beta-galactosidase in the presence of the lymphoid enhancer binding factor 1/transcription factor 3 (LEF1/TCF3) mediated signaling pathway and activated Beta-catenin (CATNB). Transgenic mice display Beta-galactosidase activity during early embryonic development in a subset of pluripotent embryonic basal cells of the epithelium and dermis of developing hair follicles. Beta-galactosidase activity is not detected in the next stage of hair follicle development, formation of hair germs. At E16.5, transgene activity reappears in hair follicles and is detectable until 18 days after birth. |
||||||||||||
References |
|
Mouse Genome Database (MGD), Gene Expression Database (GXD), Mouse Models of Human Cancer database (MMHCdb) (formerly Mouse Tumor Biology (MTB)), Gene Ontology (GO) |
||
Citing These Resources Funding Information Warranty Disclaimer, Privacy Notice, Licensing, & Copyright Send questions and comments to User Support. |
last database update 10/29/2024 MGI 6.24 |
|
|